Literature DB >> 28663431

HIV pre-exposure prophylaxis: the primary care implications of prescribing restrictions.

Ryan Wereski1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28663431      PMCID： PMC5565857          DOI： 10.3399/bjgp17X691541

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN： 0960-1643            Impact factor:   5.386


× No keyword cloud information.
  7 in total

1.  Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.

Authors:  Dara A Lehman; Jared M Baeten; Connor O McCoy; Julie F Weis; Dylan Peterson; Gerald Mbara; Deborah Donnell; Katherine K Thomas; Craig W Hendrix; Mark A Marzinke; Lisa Frenkel; Patrick Ndase; Nelly R Mugo; Connie Celum; Julie Overbaugh; Frederick A Matsen
Journal:  J Infect Dis       Date:  2015-01-13       Impact factor: 5.226

2.  Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.

Authors:  Peter L Anderson; David V Glidden; Albert Liu; Susan Buchbinder; Javier R Lama; Juan Vicente Guanira; Vanessa McMahan; Lane R Bushman; Martín Casapía; Orlando Montoya-Herrera; Valdilea G Veloso; Kenneth H Mayer; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Esper Georges Kallás; Robert M Grant
Journal:  Sci Transl Med       Date:  2012-09-12       Impact factor: 17.956

3.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

4.  Effect of pre-exposure prophylaxis and combination HIV prevention for men who have sex with men in the UK: a mathematical modelling study.

Authors:  Narat Punyacharoensin; William John Edmunds; Daniela De Angelis; Valerie Delpech; Graham Hart; Jonathan Elford; Alison Brown; O Noel Gill; Richard Guy White
Journal:  Lancet HIV       Date:  2016-01-14       Impact factor: 12.767

5.  Projected Lifetime Healthcare Costs Associated with HIV Infection.

Authors:  Fumiyo Nakagawa; Alec Miners; Colette J Smith; Ruth Simmons; Rebecca K Lodwick; Valentina Cambiano; Jens D Lundgren; Valerie Delpech; Andrew N Phillips
Journal:  PLoS One       Date:  2015-04-22       Impact factor: 3.240

6.  Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

Authors:  Sheena McCormack; David T Dunn; Monica Desai; David I Dolling; Mitzy Gafos; Richard Gilson; Ann K Sullivan; Amanda Clarke; Iain Reeves; Gabriel Schembri; Nicola Mackie; Christine Bowman; Charles J Lacey; Vanessa Apea; Michael Brady; Julie Fox; Stephen Taylor; Simone Antonucci; Saye H Khoo; James Rooney; Anthony Nardone; Martin Fisher; Alan McOwan; Andrew N Phillips; Anne M Johnson; Brian Gazzard; Owen N Gill
Journal:  Lancet       Date:  2015-09-09       Impact factor: 79.321

7.  Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-06-14       Impact factor: 17.586
  7 in total
  1 in total

1.  Pre-exposure prophylaxis and primary care.

Authors:  Des Crowley; Walter Cullen; Patrick O'Donnell
Journal:  Br J Gen Pract       Date:  2020-07-30       Impact factor: 5.386
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.